Skip to content

Clinical effect of acupuncture and moxibustion in the treatment of atherothrombosis

Clinical effect of acupuncture and moxibustion in the treatment of atherothrombosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019259
Enrollment
Unknown
Registered
2018-11-01
Start date
2017-07-01
Completion date
Unknown
Last updated
2018-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherothrombosis

Interventions

medicine group:Aspirin, Lipitor
placebo group.:placebo acupuncture and moxibustion

Sponsors

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Comply with the diagnosis of carotid atherosclerotic plaque and no history of cardiovascular events; 2. Carotid artery thickening, no active plaque, and plaque less than 5; 3. cholesterol 2.59 mmol/L8.0 mmol/L,Triglyceride 1.7 mmol/L10.0 mmol/L; 4. aged 25-70 years; 5. Medicine for treating atherosclerosis has not been used for nearly 2 weeks; 6. Voluntary participation in clinical studies and consent to the signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who do not meet the criteria for inclusion in the criteria; 2. Carotid stenosis >50%; 3. 5 and more carotid plaques; 4. Hyperlipidemia patients with cholesterol greater than 8.00mmol/L. Triglyceride is greater than 10.0mmol/L. BMI=30; 5. Have suffered from myocardial infarction, cerebrovascular accident, TIA, severe trauma or major surgery; 6. Immune system diseases, thyroid dysfunction, severe cardiopulmonary insufficiency, severe arrhythmia, angina pectoris, atrial fibrillation; 7. Liver and kidney dysfunction; mentally disabled; alcohol, drug abuse history; allergies; 8. Six risk factors including 60 years old or older, hypertension, smoking, diabetes, obesity, and low HDL-C combined with more than 4.

Design outcomes

Primary

MeasureTime frame
Carotid Artery Color Doppler Ultrasound;serum lipid metabolism;apolipoprotein A-IV;

Secondary

MeasureTime frame
platelet aggregation rate;Coagulation fibrinogen;complete blood count;

Countries

China

Contacts

Public ContactFu Wen-bin

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine

fuwenbin@139.com+86 13808888626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 26, 2026